Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

Executive Summary

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

You may also be interested in...



China Bioventures' Role In Virus Fight Helps Secure $721m In New Funding, Deals

Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.

Global Supply Chain In Historic Upheaval As 'De-China' Trend Marches On

More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.

China Tightens Clinical Study Grip In Sweeping Biosecurity Law Proposal

From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel